Axsome Therapeutics, Inc. (AXSM) stock
AXSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
$134.00−1.95 (-1.43%)
Close on Nov 18, 2026Market cap $7.02BP/E –Yield –
Axsome Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Axsome Therapeutics's total assets was $761.45M at Jun 30, 2026. For fiscal 2025 it was $689.81M, up 21.3% from the year before. Over ten years it grew 30.3% a year on average. The highest annual figure on record is $689.81M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $689.81M | +21.3% |
| FY2024 | Dec 31, 2024 | $568.50M | -3.4% |
| FY2023 | Dec 31, 2023 | $588.24M | +77.5% |
| FY2022 | Dec 31, 2022 | $331.48M | +277.6% |
| FY2021 | Dec 31, 2021 | $87.79M | -52.8% |
| FY2020 | Dec 31, 2020 | $186.13M | -15.6% |
| FY2019 | Dec 31, 2019 | $220.55M | +1334.1% |
| FY2018 | Dec 31, 2018 | $15.38M | -56.7% |
| FY2017 | Dec 31, 2017 | $35.56M | -7.0% |
| FY2016 | Dec 31, 2016 | $38.21M | -22.1% |
| FY2015 | Dec 31, 2015 | $49.08M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $761.45M | +19.0% |
| Q1 FY2026 | Mar 31, 2026 | $713.61M | +19.6% |
| Q4 FY2025 | Dec 31, 2025 | $689.81M | +21.3% |
| Q3 FY2025 | Sep 30, 2025 | $669.25M | +19.2% |
| Q2 FY2025 | Jun 30, 2025 | $639.79M | +16.7% |
| Q1 FY2025 | Mar 31, 2025 | $596.67M | +9.3% |
| Q4 FY2024 | Dec 31, 2024 | $568.50M | -3.4% |
| Q3 FY2024 | Sep 30, 2024 | $561.46M | -6.6% |
| Q2 FY2024 | Jun 30, 2024 | $548.23M | -10.4% |
| Q1 FY2024 | Mar 31, 2024 | $545.73M | +40.2% |
| Q4 FY2023 | Dec 31, 2023 | $588.24M | +77.5% |
| Q3 FY2023 | Sep 30, 2023 | $600.86M | +77.3% |
| Q2 FY2023 | Jun 30, 2023 | $611.64M | +238.7% |
| Q1 FY2023 | Mar 31, 2023 | $389.18M | +339.5% |
| Q4 FY2022 | Dec 31, 2022 | $331.48M | +277.6% |
| Q3 FY2022 | Sep 30, 2022 | $338.96M | +190.7% |
| Q2 FY2022 | Jun 30, 2022 | $180.56M | +26.0% |
| Q1 FY2022 | Mar 31, 2022 | $88.56M | -46.9% |
| Q4 FY2021 | Dec 31, 2021 | $87.79M | -52.8% |
| Q3 FY2021 | Sep 30, 2021 | $116.60M | -42.7% |
| Q2 FY2021 | Jun 30, 2021 | $143.26M | -25.0% |
| Q1 FY2021 | Mar 31, 2021 | $166.90M | -15.6% |
| Q4 FY2020 | Dec 31, 2020 | $186.13M | -15.6% |
| Q3 FY2020 | Sep 30, 2020 | $203.63M | +358.2% |
| Q2 FY2020 | Jun 30, 2020 | $190.99M | +248.7% |
| Q1 FY2020 | Mar 31, 2020 | $197.80M | +350.6% |
| Q4 FY2019 | Dec 31, 2019 | $220.55M | +1334.1% |
| Q3 FY2019 | Sep 30, 2019 | $44.44M | +175.6% |
| Q2 FY2019 | Jun 30, 2019 | $54.78M | +152.1% |
| Q1 FY2019 | Mar 31, 2019 | $43.90M | +57.1% |
| Q4 FY2018 | Dec 31, 2018 | $15.38M | -56.7% |
| Q3 FY2018 | Sep 30, 2018 | $16.13M | -50.6% |
| Q2 FY2018 | Jun 30, 2018 | $21.73M | -44.4% |
| Q1 FY2018 | Mar 31, 2018 | $27.94M | -39.8% |
| Q4 FY2017 | Dec 31, 2017 | $35.56M | -7.0% |
| Q3 FY2017 | Sep 30, 2017 | $32.62M | -6.6% |
| Q2 FY2017 | Jun 30, 2017 | $39.04M | – |
| Q1 FY2017 | Mar 31, 2017 | $46.41M | – |
| Q4 FY2016 | Dec 31, 2016 | $38.21M | – |
| Q3 FY2016 | Sep 30, 2016 | $34.92M | – |
See a number that looks wrong?